Gene: KRAS

3845
C-K-RAS|CFC2|K-RAS2A|K-RAS2B|K-RAS4A|K-RAS4B|K-Ras|KI-RAS|KRAS1|KRAS2|NS|NS3|RALD|RASK2|c-Ki-ras2
KRAS proto-oncogene, GTPase
protein-coding
12p12.1
Ensembl:ENSG00000133703 MIM:190070 Vega:OTTHUMG00000171193 UniprotKB:P01116
NG_007524.1
PubMed
0   ANCO-SNPs
ND|AD
303   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.048e-1 (AD)  1.567e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
NAPG0.969
UBE2K0.969
SLC25A460.969
SEC23A0.968
GSK3B0.966
RNF380.965
ATP6V1A0.964
NCKAP10.963
ZYG11B0.963
DNAJB140.961

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.534
OR4F29-0.487
CSAG1-0.468
MTRNR2L10-0.409
HEY2-0.399
MTRNR2L6-0.389
MTRNR2L9-0.388
MYL3-0.378
RAB13-0.359
CNN2-0.359

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB07771[(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACIDSmall MoleculeExperimentalTarget
DB07780FARNESYL DIPHOSPHATESmall MoleculeExperimentalTarget
ID Drug Name Action PubMed
C0317631,3-butadiene"1,3-butadiene results in increased mutagenesis of KRAS gene"11397402
C0326681-nitropyrene[1-nitropyrene co-treated with KC 400] results in increased mutagenesis of KRAS gene10396879
C0326681-nitropyrene[1-nitropyrene co-treated with Polychlorinated Biphenyls] results in increased mutagenesis of KRAS gene11746253
C0326681-nitropyrene1-nitropyrene results in increased mutagenesis of KRAS gene10396879|1174625
C0326681-nitropyrene[Bleomycin co-treated with 1-nitropyrene] results in increased mutagenesis of KRAS gene12616606
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [KRAS protein mutant form results in increased susceptibility to GDC-0973]"22084396
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"GDC-0973 promotes the reaction [KRAS protein mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine]"22084396
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"KRAS gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"23136191
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"KRAS protein mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"22084396
C0939732-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [KRAS protein mutant form results in increased expression of GGT2 mRNA]22269385
C0600802,2-bis(bromomethyl)-1,3-propanediol"2,2-bis(bromomethyl)-1,3-propanediol results in increased mutagenesis of KRAS gene"14713543
C0010422',3-dimethyl-4-aminobiphenyl"2',3-dimethyl-4-aminobiphenyl results in increased mutagenesis of KRAS gene"7766307
C0164032,4-dinitrotoluene"2,4-dinitrotoluene affects the expression of KRAS mRNA"21346803
C0369902-amino-3,8-dimethylimidazo(4,5-f)quinoxaline"2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased mutagenesis of KRAS gene"18271921
C0292162-amino-3-methylimidazo(4,5-f)quinoline"2-amino-3-methylimidazo(4,5-f)quinoline results in increased mutagenesis of KRAS gene"8844820
C0303702-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone"2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone results in decreased expression of KRAS mRNA"20206263
C0132793,4,3',4'-tetrachloroazobenzene"3,4,3',4'-tetrachloroazobenzene results in increased mutagenesis of KRAS gene"23703846
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KRAS mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KRAS mRNA"27188386
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone[Lipopolysaccharides co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in increased mutagenesis of KRAS gene21868532
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased mutagenesis of KRAS gene18271921
C0126064-vinyl-1-cyclohexene dioxide4-vinyl-1-cyclohexene dioxide affects the expression of KRAS mRNA20829426
C0084225-methylchrysene5-methylchrysene results in increased mutagenesis of KRAS gene8571376|9659573
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KRAS mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KRAS mRNA"27188386
D000082AcetaminophenAcetaminophen affects the expression of KRAS mRNA17562736
D000111AcetylcysteineAcetylcysteine inhibits the reaction [manumycin results in decreased activity of KRAS protein]19409983
D000171AcroleinAcrolein results in decreased expression of KRAS protein24812010
D000643Ammonium ChlorideAmmonium Chloride affects the expression of KRAS mRNA16483693
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of KRAS mRNA24449571
C000228aristolochic acid Iaristolochic acid I results in increased mutagenesis of KRAS gene21642617
D001151ArsenicKRAS affects the reaction [Arsenic results in increased phosphorylation of MAPK1 protein]25273566
D001151ArsenicKRAS affects the reaction [Arsenic results in increased phosphorylation of MAPK3 protein]25273566
D001151ArsenicKRAS affects the reaction [Arsenic results in increased secretion of MMP9 protein]25273566
D001151ArsenicKRAS affects the susceptibility to Arsenic25273566
C015001arsenitearsenite results in increased expression of KRAS protein24704393
C015001arsenitedecitabine inhibits the reaction [arsenite results in increased expression of KRAS protein]24704393
C015001arseniteMIRLET7C mRNA inhibits the reaction [arsenite results in increased expression of KRAS protein]24704393
D001194AsbestosAsbestos results in increased mutagenesis of KRAS gene12725029
C517975AZD 6244AZD 6244 inhibits the reaction [KRAS protein mutant form affects the susceptibility to vemurafenib]27222248
C517975AZD 6244AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]27222248
C517975AZD 6244AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]27222248
C517975AZD 6244AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]27222248
C517975AZD 6244AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]27222248
C517975AZD 6244AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein]27222248
C517975AZD 6244AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein]27222248
D001397AzoxymethaneAzoxymethane results in increased mutagenesis of KRAS gene12839936|2137028
D001397AzoxymethaneUrsodeoxycholic Acid inhibits the reaction [Azoxymethane results in increased mutagenesis of KRAS gene]12839936
D001554BenzeneKRAS gene polymorphism results in increased susceptibility to Benzene12807761
C037411benz(j)aceanthrylenebenz(j)aceanthrylene results in increased mutagenesis of KRAS gene9659573
C006703benzo(b)fluoranthenebenzo(b)fluoranthene results in increased mutagenesis of KRAS gene8571376|9659573
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of KRAS mRNA22228805
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased mutagenesis of KRAS gene19658153|8571376
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of KRAS mRNA"19150397|2001819
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of KRAS mRNA"18567617
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of KRAS protein"18567617
D001580BenzopyrenesBenzopyrenes results in increased mutagenesis of KRAS gene10656603
C018847benzotrichloridebenzotrichloride results in increased mutagenesis of KRAS gene8508514
D004958EstradiolEstradiol results in decreased expression of KRAS mRNA16474171
D004958EstradiolEstradiol results in increased expression of KRAS mRNA23094148
C006780bisphenol Abisphenol A results in decreased expression of KRAS mRNA16474171
C006780bisphenol Abisphenol A results in increased mutagenesis of KRAS gene11342245
C006780bisphenol Abisphenol A results in increased expression of KRAS mRNA26063408
C006780bisphenol Abisphenol A affects the expression of KRAS mRNA25181051
C006780bisphenol Abisphenol A results in increased expression of KRAS mRNA29097150
C006780bisphenol Abisphenol A results in increased methylation of KRAS gene28505145
C006780bisphenol Abisphenol A binds to KRAS protein24266771
D001761Bleomycin[Bleomycin co-treated with 1-nitropyrene] results in increased mutagenesis of KRAS gene12616606
D002084Butylated HydroxytolueneButylated Hydroxytoluene results in increased mutagenesis of KRAS gene20101149
D002104CadmiumCadmium results in decreased expression of KRAS mRNA21120746
D002104CadmiumCadmium results in increased expression of KRAS mRNA20049202
D002104CadmiumCadmium results in increased expression of KRAS protein20049202
D019256Cadmium ChlorideCadmium Chloride results in increased expression of KRAS mRNA26472689
D019256Cadmium ChlorideCadmium Chloride results in increased expression of KRAS protein23811327|2751046
D019256Cadmium ChlorideKRAS protein inhibits the reaction [Cadmium Chloride results in decreased expression of MIR155 mRNA]27510461
D019256Cadmium ChlorideKRAS protein inhibits the reaction [Cadmium Chloride results in decreased expression of MIR205 mRNA]27510461
D019256Cadmium ChlorideKRAS protein inhibits the reaction [Cadmium Chloride results in increased expression of MIR134 mRNA]27510461
D019256Cadmium ChlorideKRAS protein promotes the reaction [Cadmium Chloride results in increased expression of MAPK1 protein modified form]27510461
D019256Cadmium ChlorideKRAS protein promotes the reaction [Cadmium Chloride results in increased expression of MAPK3 protein modified form]27510461
D019256Cadmium ChlorideKRAS protein promotes the reaction [Cadmium Chloride results in increased secretion of MMP2 protein]27510461
D002220CarbamazepineCarbamazepine affects the expression of KRAS mRNA24752500
C016482carbon fibercarbon fiber results in increased mutagenesis of KRAS gene24213921
D002251Carbon TetrachlorideCarbon Tetrachloride affects the expression of KRAS mRNA17484886
D002251Carbon TetrachlorideCarbon Tetrachloride results in increased expression of KRAS mRNA8847708
D002108CeruletideIL6 protein inhibits the reaction [(+)-JQ1 compound inhibits the reaction [[KRAS protein mutant form co-treated with Ceruletide] results in increased phosphorylation of STAT3 protein]]26390243
D002108Ceruletide(+)-JQ1 compound inhibits the reaction [[KRAS protein mutant form co-treated with Ceruletide] results in increased expression of BRD4 protein]26390243
D002108Ceruletide(+)-JQ1 compound inhibits the reaction [[KRAS protein mutant form co-treated with Ceruletide] results in increased expression of IL6 protein]26390243
D002108Ceruletide(+)-JQ1 compound inhibits the reaction [[KRAS protein mutant form co-treated with Ceruletide] results in increased phosphorylation of AKT1 protein]26390243
D002108Ceruletide(+)-JQ1 compound inhibits the reaction [[KRAS protein mutant form co-treated with Ceruletide] results in increased phosphorylation of STAT3 protein]26390243
D002108Ceruletide[KRAS protein mutant form co-treated with Ceruletide] results in increased expression of BRD4 protein26390243
D002108Ceruletide[KRAS protein mutant form co-treated with Ceruletide] results in increased expression of IL6 protein26390243
D002108Ceruletide[KRAS protein mutant form co-treated with Ceruletide] results in increased phosphorylation of AKT1 protein26390243
D002108Ceruletide[KRAS protein mutant form co-treated with Ceruletide] results in increased phosphorylation of STAT3 protein26390243
D002713Chlorine[Ozone co-treated with Chlorine] results in decreased expression of KRAS mRNA18636392
D020111Chlorodiphenyl (54% Chlorine)Chlorodiphenyl (54% Chlorine) affects the localization of KRAS protein9525281
D020111Chlorodiphenyl (54% Chlorine)Chlorodiphenyl (54% Chlorine) results in decreased expression of KRAS mRNA23650126
D020111Chlorodiphenyl (54% Chlorine)Chlorodiphenyl (54% Chlorine) results in decreased expression of KRAS protein23650126
D020245p-Chloromercuribenzoic Acid"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KRAS mRNA"27188386
D020245p-Chloromercuribenzoic Acidp-Chloromercuribenzoic Acid results in decreased expression of KRAS mRNA26272509
D002737ChloropreneChloroprene results in increased mutagenesis of KRAS gene10223196|1139740
D004390ChlorpyrifosChlorpyrifos results in decreased expression of KRAS mRNA18668222
D002994ClofibrateClofibrate results in increased expression of KRAS mRNA23811191
D004396Coloring AgentsColoring Agents results in increased mutagenesis of KRAS gene14520703
D003300CopperCopper deficiency results in increased expression of KRAS mRNA17418555
D003300CopperCopper results in increased expression of KRAS mRNA22465980
D019327Copper SulfateCopper Sulfate results in decreased expression of KRAS mRNA19789285
D003375CoumestrolCoumestrol results in decreased expression of KRAS mRNA19167446
C551994crizotinibKRAS protein mutant form results in decreased susceptibility to crizotinib22235099
C015763cumene[cumene co-treated with KRAS gene mutant form] results in decreased expression of CEBPD mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in decreased expression of CKS1B mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in decreased expression of CYR61 mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in decreased expression of DLC1 mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in decreased expression of DUSP14 mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in decreased expression of DUSP3 mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in decreased expression of ENO1 mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in decreased expression of ENPP2 mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in decreased expression of EPCAM mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in decreased expression of GPER1 mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in decreased expression of IGFBP4 mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in decreased expression of KRT18 mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in decreased expression of KRT8 mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in decreased expression of LASP1 mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in decreased expression of MMP14 mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in decreased expression of RACK1 mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in decreased expression of RB1 mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in decreased expression of SDC1 mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in decreased expression of SLC2A1 mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in decreased expression of SOD3 mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in decreased expression of SRD5A1 mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in decreased expression of VWF mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in increased expression of AREG mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in increased expression of CCND1 mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in increased expression of EREG mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in increased expression of KLF5 mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in increased expression of LAMTOR2 mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in increased expression of MAP2K1 mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in increased expression of MAP2K1 protein18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in increased expression of MIF mRNA18648096
C015763cumene[cumene co-treated with KRAS gene mutant form] results in increased expression of PTGES mRNA18648096
C015763cumeneKRAS gene mutant form promotes the reaction [cumene results in increased expression of CLU mRNA]18648096
D003471CuprizoneCuprizone results in decreased expression of KRAS mRNA26577399
D003474CurcuminCurcumin analog results in decreased expression of KRAS mRNA17041101
D003474CurcuminCurcumin results in decreased expression of KRAS mRNA17041101
D003474CurcuminCurcumin affects the reaction [KRAS protein affects the localization of TRP53 protein]21519798
D003474CurcuminCurcumin inhibits the reaction [KRAS protein results in decreased expression of XPO1 protein]21519798
D003513CycloheximideCycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of KRAS mRNA]11007951
C016328cyclopenta(c,d)pyrene"cyclopenta(c,d)pyrene results in increased mutagenesis of KRAS gene"9659573
C561627dabrafenibKRAS protein affects the susceptibility to dabrafenib27222248
C561627dabrafenib[KRAS protein affects the susceptibility to dabrafenib] which affects the expression of TNFRSF10B protein27222248
C561627dabrafenib[KRAS protein affects the susceptibility to dabrafenib] which affects the phosphorylation of MAPK1 protein27222248
C561627dabrafenib[KRAS protein affects the susceptibility to dabrafenib] which affects the phosphorylation of MAPK3 protein27222248
D003609DactinomycinDactinomycin inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B mRNA]27222248
C014347decitabinedecitabine inhibits the reaction [arsenite results in increased expression of KRAS protein]24704393
D003687DehydroepiandrosteroneDehydroepiandrosterone results in increased mutagenesis of KRAS gene8603461
D013759DronabinolDronabinol results in increased expression of KRAS mRNA16597638
D013759DronabinolDronabinol results in increased expression of KRAS2540743
C068327diallyl sulfonediallyl sulfone inhibits the reaction [vinyl carbamate results in increased mutagenesis of KRAS gene]20205516
C041517dibenzo(a,l)pyrene"dibenzo(a,l)pyrene results in increased mutagenesis of KRAS gene"9659573
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in decreased expression of KRAS mRNA27392435
D002945CisplatinCisplatin results in decreased expression of KRAS mRNA27392435
D004008DiclofenacDiclofenac affects the expression of KRAS mRNA24752500
D004052DiethylnitrosamineDiethylnitrosamine results in increased expression of KRAS mRNA26464624
D004052DiethylnitrosamineDiethylnitrosamine results in increased expression of KRAS mRNA7910516
C012457diisopropanolnitrosaminediisopropanolnitrosamine results in increased mutagenesis of KRAS gene18271921
D004128DimethylnitrosamineDimethylnitrosamine affects the localization of KRAS protein11884234
D004128DimethylnitrosamineDimethylnitrosamine results in decreased expression of and affects the localization of KRAS protein19555203
D004128DimethylnitrosamineTetrachlorodibenzodioxin promotes the reaction [Dimethylnitrosamine affects the localization of KRAS protein]11884234
D004128DimethylnitrosamineTetrachlorodibenzodioxin promotes the reaction [Dimethylnitrosamine results in decreased expression of KRAS protein]19555203
D004365Drugs, Chinese Herbal"Drugs, Chinese Herbal results in decreased expression of KRAS mRNA"12747207
D000069347Erlotinib HydrochlorideKRAS protein results in increased susceptibility to Erlotinib Hydrochloride20705357
D004997Ethinyl Estradiol[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of KRAS mRNA17942748
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of KRAS mRNA29097150
D005027Ethylene OxideEthylene Oxide results in increased mutagenesis of KRAS gene24029818
D005038EthylnitrosoureaEthylnitrosourea promotes the reaction [GATA6 protein binds to KRAS exon]16271038
D005038EthylnitrosoureaEthylnitrosourea promotes the reaction [NFYA protein binds to KRAS exon]16271038
D005038EthylnitrosoureaEthylnitrosourea results in increased mutagenesis of KRAS gene15790496
C004808farnesyl pyrophosphate[FNTA protein binds to FNTB protein] binds to [farnesyl pyrophosphate analog co-treated with KRAS protein]10673434
D005472FluorouracilFluorouracil results in decreased expression of KRAS protein15585135|1680352
D005485FlutamideFlutamide results in increased expression of KRAS mRNA24136188
D005492Folic AcidFolic Acid results in increased expression of KRAS mRNA2566606
C574276GDC-0973"2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [KRAS protein mutant form results in increased susceptibility to GDC-0973]"22084396
C574276GDC-0973"GDC-0973 promotes the reaction [KRAS protein mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine]"22084396
C574276GDC-0973KRAS protein mutant form results in increased susceptibility to GDC-097322084396
C419708gefitinibKRAS protein affects the reaction [EGFR protein affects the susceptibility to gefitinib]28739874
C419708gefitinibKRAS protein mutant form affects the susceptibility to gefitinib17270025
C419708gefitinibKRAS protein results in decreased susceptibility to gefitinib28739874
D019833GenisteinGenistein results in decreased expression of KRAS mRNA15256057|1647417
D005839GentamicinsGentamicins results in increased expression of KRAS mRNA22061828
C466792GGTI 2147[GGTI 2147 co-treated with L 744832] results in decreased prenylation of KRAS protein16156861
D006151GuanosineGuanosine inhibits the reaction [tiazofurin results in decreased expression of KRAS]9381980
D006153Guanosine DiphosphateGuanosine Diphosphate binds to KRAS protein28154176
D006153Guanosine DiphosphateGuanosine Diphosphate binds to KRAS protein mutant form28154176
D006153Guanosine DiphosphateKRAS protein mutant form inhibits the reaction [SOS1 protein inhibits the reaction [Guanosine Diphosphate binds to KRAS protein]]28154176
D006153Guanosine DiphosphateSOS1 protein inhibits the reaction [Guanosine Diphosphate binds to KRAS protein]28154176
D006160Guanosine TriphosphateGuanosine Triphosphate binds to KRAS protein28154176
D006160Guanosine TriphosphateGuanosine Triphosphate binds to KRAS protein mutant form28154176
D006160Guanosine TriphosphateKRAS protein mutant form inhibits the reaction [RASA1 protein promotes the reaction [KRAS protein results in increased hydrolysis of Guanosine Triphosphate]]28154176
D006160Guanosine TriphosphateKRAS protein mutant form results in increased hydrolysis of Guanosine Triphosphate28154176
D006160Guanosine TriphosphateKRAS protein results in increased hydrolysis of Guanosine Triphosphate28154176
D006160Guanosine TriphosphateRASA1 protein promotes the reaction [KRAS protein results in increased hydrolysis of Guanosine Triphosphate]28154176
D006220HaloperidolHaloperidol results in increased expression of KRAS mRNA15860345
D006861Hydrogen PeroxideGGT2 protein affects the reaction [KRAS protein mutant form results in decreased susceptibility to Hydrogen Peroxide]22269385
D006861Hydrogen PeroxideKRAS protein mutant form inhibits the reaction [Hydrogen Peroxide affects the localization of CYCS protein]22269385
D006861Hydrogen PeroxideKRAS protein mutant form inhibits the reaction [Hydrogen Peroxide results in increased chemical synthesis of Reactive Oxygen Species]22269385
D006861Hydrogen PeroxideKRAS protein mutant form inhibits the reaction [Hydrogen Peroxide results in increased cleavage of and results in increased activity of CASP3 protein]22269385
D006861Hydrogen PeroxideKRAS protein mutant form inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX protein]22269385
D006861Hydrogen PeroxideKRAS protein mutant form inhibits the reaction [Hydrogen Peroxide results in increased expression of HSPA5 protein]22269385
D006861Hydrogen Peroxide[KRAS protein mutant form results in decreased chemical synthesis of Reactive Oxygen Species] which results in decreased susceptibility to Hydrogen Peroxide22269385
D006861Hydrogen PeroxideKRAS protein mutant form results in decreased susceptibility to Hydrogen Peroxide22269385
D006861Hydrogen Peroxide[KRAS protein results in increased activity of GGT2 protein] which results in decreased susceptibility to Hydrogen Peroxide22269385
C031927hydroquinone[PARP1 protein affects the susceptibility to hydroquinone] which affects the expression of KRAS protein28444915
D006918HydroxyureaHydroxyurea results in decreased expression of KRAS mRNA12929121
D015759IonomycinMethohexital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]15263067
D015759IonomycinPentobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]15263067
D015759IonomycinSecobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]15263067
D015759IonomycinThiamylal inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]15263067
C005059isopreneisoprene results in increased mutagenesis of KRAS gene11397402|9111215
D007545IsoproterenolIsoproterenol results in increased expression of KRAS mRNA21335049
C544151jinfukang[Cisplatin co-treated with jinfukang] results in decreased expression of KRAS mRNA27392435
C544151jinfukangjinfukang results in decreased expression of KRAS mRNA27392435
C561695(+)-JQ1 compoundKRAS gene mutant form results in increased susceptibility to (+)-JQ1 compound24045185
C561695(+)-JQ1 compound[KRAS gene mutant form results in increased susceptibility to (+)-JQ1 compound] which affects the localization of BRD4 protein24045185
C561695(+)-JQ1 compound[KRAS gene mutant form results in increased susceptibility to (+)-JQ1 compound] which results in decreased expression of MYC protein24045185
C561695(+)-JQ1 compound[KRAS gene mutant form results in increased susceptibility to (+)-JQ1 compound] which results in increased activity of CASP3 protein24045185
C561695(+)-JQ1 compound[KRAS gene mutant form results in increased susceptibility to (+)-JQ1 compound] which results in increased cleavage of PARP1 protein24045185
C561695(+)-JQ1 compoundSTK11 gene mutant form inhibits the reaction [KRAS gene mutant form results in increased susceptibility to (+)-JQ1 compound]24045185
C561695(+)-JQ1 compoundSTK11 gene mutant form inhibits the reaction [[KRAS gene mutant form results in increased susceptibility to (+)-JQ1 compound] which results in increased activity of CASP3 protein]24045185
C561695(+)-JQ1 compoundSTK11 gene mutant form inhibits the reaction [[KRAS gene mutant form results in increased susceptibility to (+)-JQ1 compound] which results in increased cleavage of PARP1 protein]24045185
C561695(+)-JQ1 compoundIL6 protein inhibits the reaction [(+)-JQ1 compound inhibits the reaction [[KRAS protein mutant form co-treated with Ceruletide] results in increased phosphorylation of STAT3 protein]]26390243
C561695(+)-JQ1 compound(+)-JQ1 compound inhibits the reaction [KRAS gene mutant form results in increased expression of MYC protein]26390243
C561695(+)-JQ1 compound(+)-JQ1 compound inhibits the reaction [[KRAS mutant form co-treated with TRP53 mutant form] results in increased expression of BRD4 protein]26390243
C561695(+)-JQ1 compound(+)-JQ1 compound inhibits the reaction [[KRAS mutant form co-treated with TRP53 mutant form] results in increased expression of CSF2 protein]26390243
C561695(+)-JQ1 compound(+)-JQ1 compound inhibits the reaction [[KRAS mutant form co-treated with TRP53 mutant form] results in increased expression of CSF3 protein]26390243
C561695(+)-JQ1 compound(+)-JQ1 compound inhibits the reaction [[KRAS mutant form co-treated with TRP53 mutant form] results in increased expression of IL1A protein]26390243
C561695(+)-JQ1 compound(+)-JQ1 compound inhibits the reaction [[KRAS mutant form co-treated with TRP53 mutant form] results in increased expression of IL1B protein]26390243
C561695(+)-JQ1 compound(+)-JQ1 compound inhibits the reaction [[KRAS mutant form co-treated with TRP53 mutant form] results in increased expression of IL2 protein]26390243
C561695(+)-JQ1 compound(+)-JQ1 compound inhibits the reaction [[KRAS mutant form co-treated with TRP53 mutant form] results in increased expression of IL4 protein]26390243
C561695(+)-JQ1 compound(+)-JQ1 compound inhibits the reaction [[KRAS mutant form co-treated with TRP53 mutant form] results in increased expression of IL6 protein]26390243
C561695(+)-JQ1 compound(+)-JQ1 compound inhibits the reaction [[KRAS mutant form co-treated with TRP53 mutant form] results in increased expression of MYC protein]26390243
C561695(+)-JQ1 compound(+)-JQ1 compound inhibits the reaction [[KRAS mutant form co-treated with TRP53 mutant form] results in increased phosphorylation of AKT1 protein]26390243
C561695(+)-JQ1 compound(+)-JQ1 compound inhibits the reaction [[KRAS mutant form co-treated with TRP53 mutant form] results in increased phosphorylation of STAT3 protein]26390243
C561695(+)-JQ1 compound(+)-JQ1 compound inhibits the reaction [[KRAS protein mutant form co-treated with Ceruletide] results in increased expression of BRD4 protein]26390243
C561695(+)-JQ1 compound(+)-JQ1 compound inhibits the reaction [[KRAS protein mutant form co-treated with Ceruletide] results in increased expression of IL6 protein]26390243
C561695(+)-JQ1 compound(+)-JQ1 compound inhibits the reaction [[KRAS protein mutant form co-treated with Ceruletide] results in increased phosphorylation of AKT1 protein]26390243
C561695(+)-JQ1 compound(+)-JQ1 compound inhibits the reaction [[KRAS protein mutant form co-treated with Ceruletide] results in increased phosphorylation of STAT3 protein]26390243
C561695(+)-JQ1 compound[KRAS gene mutant form results in increased susceptibility to (+)-JQ1 compound] which results in decreased expression of MYC mRNA24045185
C561695(+)-JQ1 compound[KRAS gene mutant form results in increased susceptibility to (+)-JQ1 compound] which results in decreased expression of MYC protein24045185
C561695(+)-JQ1 compound[KRAS gene mutant form results in increased susceptibility to (+)-JQ1 compound] which results in increased expression of BRD4 protein24045185
C561695(+)-JQ1 compoundSTK11 gene mutant form affects the reaction [[KRAS gene mutant form results in increased susceptibility to (+)-JQ1 compound] which results in decreased expression of MYC protein]24045185
C561695(+)-JQ1 compoundSTK11 gene mutant form affects the reaction [[KRAS gene mutant form results in increased susceptibility to (+)-JQ1 compound] which results in increased expression of BRD4 protein]24045185
C410337K 7174K 7174 results in increased expression of KRAS mRNA24086573
D007608Kainic AcidKainic Acid results in increased expression of KRAS mRNA19700661
C039772KC 400[1-nitropyrene co-treated with KC 400] results in increased mutagenesis of KRAS gene10396879
C096898L 744832[GGTI 2147 co-treated with L 744832] results in decreased prenylation of KRAS protein16156861
C490728lapatinibKRAS protein affects the reaction [EGFR protein affects the susceptibility to lapatinib]28739874
C490728lapatinibKRAS protein results in decreased susceptibility to lapatinib28739874
D007854LeadLead results in increased expression of KRAS protein19727529
C008261lead acetate[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of KRAS mRNA22839698
C008261lead acetatelead acetate results in decreased expression of KRAS mRNA21829687
C008261lead acetatelead acetate results in increased expression of KRAS mRNA25270620
D008070Lipopolysaccharides[Lipopolysaccharides co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in increased mutagenesis of KRAS gene21868532
D008148LovastatinLovastatin results in decreased prenylation of KRAS protein16156861
D008148LovastatinLovastatin affects the localization of KRAS protein12106604
D008148LovastatinLovastatin results in increased activity of KRAS protein17005160
D008148LovastatinLovastatin results in increased expression of KRAS protein12907238
C054474manumycinAcetylcysteine inhibits the reaction [manumycin results in decreased activity of KRAS protein]19409983
C054474manumycinmanumycin results in decreased activity of KRAS protein19409983
C042720mercuric bromidemercuric bromide results in decreased expression of KRAS mRNA26272509
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KRAS mRNA"27188386
D008723MethohexitalMethohexital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]15263067
D008727MethotrexateKRAS gene mutant form results in increased susceptibility to Methotrexate24688052
D008727MethotrexateMethotrexate results in decreased expression of KRAS mRNA24688052
D008727MethotrexateMethotrexate results in decreased expression of KRAS mRNA mutant form24688052
D008727MethotrexateMethotrexate results in decreased expression of KRAS protein24688052
D008748MethylcholanthreneMethylcholanthrene promotes the reaction [GATA6 protein binds to KRAS exon]16271038
D008748MethylcholanthreneMethylcholanthrene promotes the reaction [NFYA protein binds to KRAS exon]16271038
D008748MethylcholanthreneMethylcholanthrene results in increased mutagenesis of KRAS gene11195466|2010114
D008770MethylnitrosoureaMethylnitrosourea results in increased mutagenesis of KRAS gene12483526|1806296
D008770MethylnitrosoureaKRAS protein results in decreased susceptibility to Methylnitrosourea11973638
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased mutagenesis of KRAS gene"24213921
D009525NiacinNiacin affects the localization of KRAS protein12106604
C028007nickel monoxidenickel monoxide results in decreased expression of KRAS mRNA19167457
C532252oncrasin-1KRAS protein mutant form results in increased susceptibility to oncrasin-121443218
D010126Ozone[Ozone co-treated with Chlorine] results in decreased expression of KRAS mRNA18636392
D010126OzoneOzone results in increased expression of KRAS mRNA16330353
D052638Particulate MatterParticulate Matter results in increased expression of KRAS mRNA24769257
D052638Particulate MatterParticulate Matter analog results in increased mutagenesis of KRAS gene9455688
D000068437PemetrexedKRAS gene mutant form results in increased susceptibility to Pemetrexed24688052
D000068437PemetrexedPemetrexed results in decreased expression of KRAS mRNA24688052
D000068437PemetrexedPemetrexed results in decreased expression of KRAS mRNA mutant form24688052
D000068437PemetrexedPemetrexed results in decreased expression of KRAS protein24688052
C086401pentabromodiphenyl etherpentabromodiphenyl ether results in increased expression of KRAS mRNA23948077
D010424PentobarbitalPentobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]15263067
D010695PhlorhizinPhlorhizin results in decreased expression of KRAS mRNA22538082
D010852PicrotoxinPicrotoxin results in decreased expression of KRAS mRNA15170462
D010882Piperonyl ButoxidePiperonyl Butoxide results in increased mutagenesis of KRAS gene7565889
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of KRAS mRNA19710929
D010936Plant ExtractsPlant Extracts results in increased expression of KRAS mRNA23557933
D011078Polychlorinated BiphenylsPolychlorinated Biphenyls analog results in decreased expression of KRAS mRNA16474171
D011078Polychlorinated Biphenyls[1-nitropyrene co-treated with Polychlorinated Biphenyls] results in increased mutagenesis of KRAS gene11746253
D011794QuercetinQuercetin inhibits the reaction [KRAS protein affects the activity of TP53 protein]19424582
D011794QuercetinQuercetin results in decreased expression of KRAS mRNA10652438|9381980
D011794QuercetinQuercetin results in decreased expression of KRAS protein10652438
D017382Reactive Oxygen SpeciesKRAS protein mutant form inhibits the reaction [Hydrogen Peroxide results in increased chemical synthesis of Reactive Oxygen Species]22269385
D017382Reactive Oxygen Species[KRAS protein mutant form results in decreased chemical synthesis of Reactive Oxygen Species] which results in decreased susceptibility to Hydrogen Peroxide22269385
C052785rebamipiderebamipide results in increased expression of KRAS mRNA18299717
C059514resveratrolresveratrol results in decreased expression of KRAS mRNA12002526|1256957
C059514resveratrolresveratrol results in decreased expression of KRAS protein25280562
C059514resveratrolresveratrol results in decreased expression of KRAS protein mutant form25280562
D015474IsotretinoinIsotretinoin results in decreased expression of KRAS mRNA20436886
C013672riddelliineriddelliine results in increased mutagenesis of KRAS gene13678655|2073700
D012631SecobarbitalSecobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]15263067
D019821SimvastatinSimvastatin results in decreased prenylation of KRAS protein8063617
D012906SmokeSmoke results in increased mutagenesis of KRAS gene20101149
C009277sodium arsenatesodium arsenate results in increased expression of KRAS mRNA23922661
C017947sodium arsenitesodium arsenite affects the expression of KRAS protein17384772
C017947sodium arsenitesodium arsenite results in increased expression of KRAS protein24431212|2580488
C017947sodium arsenitesodium arsenite affects the expression of KRAS mRNA16507464
C017947sodium arsenite[sodium arsenite co-treated with Tetradecanoylphorbol Acetate] results in increased expression of KRAS mRNA16368122
C017947sodium arsenite[sodium arsenite co-treated with Tetradecanoylphorbol Acetate] results in increased expression of KRAS protein16368122
C017947sodium arsenitesodium arsenite results in increased expression of KRAS mRNA16014739
C017947sodium arsenitesodium arsenite results in increased expression of KRAS protein16507464
C017947sodium arsenitesodium arsenite results in increased expression of KRAS mRNA11241755
D012999SomanSoman results in increased expression of KRAS mRNA19281266
D053260SootSoot results in decreased expression of KRAS mRNA22461453
D020058StyreneKRAS gene polymorphism results in increased susceptibility to Styrene12807761
D013458Sulfur DioxideSulfur Dioxide results in increased expression of KRAS mRNA19434695
D013458Sulfur DioxideSulfur Dioxide results in increased expression of KRAS protein19434695
D013467SulindacKRAS protein affects the susceptibility to Sulindac11751493
D016559TacrolimusTacrolimus results in increased expression of KRAS mRNA25270620
C004648testosterone enanthatetestosterone enanthate affects the expression of KRAS mRNA17440010
D013749TetrachlorodibenzodioxinCycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of KRAS mRNA]11007951
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of KRAS mRNA22298810
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of KRAS mRNA11007951|2010694
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of KRAS mRNA21570461
D013749Tetrachlorodibenzodioxin[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of KRAS mRNA17942748
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin promotes the reaction [Dimethylnitrosamine affects the localization of KRAS protein]11884234
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin promotes the reaction [Dimethylnitrosamine results in decreased expression of KRAS protein]19555203
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of KRAS mRNA14708085
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of and affects the localization of KRAS protein9525281
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of KRAS mRNA19465110
D013755Tetradecanoylphorbol AcetateMethohexital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]15263067
D013755Tetradecanoylphorbol AcetatePentobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]15263067
D013755Tetradecanoylphorbol AcetateSecobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]15263067
D013755Tetradecanoylphorbol AcetateThiamylal inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]15263067
D013755Tetradecanoylphorbol Acetate[sodium arsenite co-treated with Tetradecanoylphorbol Acetate] results in increased expression of KRAS mRNA16368122
D013755Tetradecanoylphorbol Acetate[sodium arsenite co-treated with Tetradecanoylphorbol Acetate] results in increased expression of KRAS protein16368122
D013774TetranitromethaneTetranitromethane results in increased mutagenesis of KRAS gene14713543
D013840ThiamylalThiamylal inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]15263067
D013849ThimerosalThimerosal results in decreased expression of KRAS mRNA27188386
C033706tiazofurinGuanosine inhibits the reaction [tiazofurin results in decreased expression of KRAS]9381980
C033706tiazofurintiazofurin results in decreased expression of KRAS9381980
C402769tipifarnibtipifarnib results in increased expression of KRAS mRNA16403772
C009495titanium dioxidetitanium dioxide affects the expression of KRAS mRNA17656681
C009495titanium dioxidetitanium dioxide results in decreased expression of KRAS mRNA23557971
D014028Tobacco Smoke PollutionTobacco Smoke Pollution results in increased mutagenesis of KRAS gene10824542|1174523
D014050TolueneToluene affects the expression of KRAS mRNA21827849
D014118Toxins, Biological"Toxins, Biological affects the expression of KRAS mRNA"19682533
C012071triazinateKRAS gene mutant form results in increased susceptibility to triazinate24688052
D016597TrimetrexateKRAS gene mutant form results in increased susceptibility to Trimetrexate24688052
C001899triptolidetriptolide results in increased expression of KRAS mRNA23639586
D014520UrethaneUrethane results in decreased expression of KRAS mRNA28818685
D014520UrethaneKRAS gene affects the susceptibility to Urethane11807781
D014520UrethaneUrethane results in decreased expression of KRAS mRNA16289808
D014520UrethaneUrethane results in increased mutagenesis of KRAS gene10779650
D014520UrethaneUrethane results in increased mutagenesis of KRAS gene18271921
D014580Ursodeoxycholic AcidUrsodeoxycholic Acid inhibits the reaction [Azoxymethane results in increased mutagenesis of KRAS gene]12839936
D014635Valproic AcidValproic Acid results in increased expression of KRAS mRNA28001369
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of KRAS gene25560391
C551177vemurafenibAZD 6244 inhibits the reaction [KRAS protein mutant form affects the susceptibility to vemurafenib]27222248
C551177vemurafenibAZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]27222248
C551177vemurafenibAZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]27222248
C551177vemurafenibAZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]27222248
C551177vemurafenibAZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]27222248
C551177vemurafenibAZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein]27222248
C551177vemurafenibAZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein]27222248
C551177vemurafenibDactinomycin inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B mRNA]27222248
C551177vemurafenibDDIT3 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]27222248
C551177vemurafenibELK1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]27222248
C551177vemurafenibKRAS protein mutant form affects the susceptibility to vemurafenib27222248
C551177vemurafenib[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]27222248
C551177vemurafenib[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]27222248
C551177vemurafenib[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]27222248
C551177vemurafenib[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of DDIT3 protein27222248
C551177vemurafenib[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of ERN1 protein27222248
C551177vemurafenib[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of HSPA5 protein27222248
C551177vemurafenib[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B mRNA27222248
C551177vemurafenib[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein27222248
C551177vemurafenib[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of ELK1 protein27222248
C551177vemurafenib[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein27222248
C551177vemurafenib[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein27222248
C551177vemurafenibMAPK1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]27222248
C551177vemurafenibMAPK3 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]27222248
C551177vemurafenibRAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]27222248
C551177vemurafenibRAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]27222248
C551177vemurafenibRAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]27222248
C551177vemurafenibRAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]27222248
C551177vemurafenibRAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein]27222248
C551177vemurafenibRAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein]27222248
C551177vemurafenibvemurafenib promotes the reaction [KRAS protein mutant form results in increased expression of TNFRSF10B mRNA]27222248
C551177vemurafenibvemurafenib promotes the reaction [KRAS protein mutant form results in increased expression of TNFRSF10B protein]27222248
C551177vemurafenibvemurafenib promotes the reaction [KRAS protein mutant form results in increased phosphorylation of MAPK1 protein]27222248
C551177vemurafenibvemurafenib promotes the reaction [KRAS protein mutant form results in increased phosphorylation of MAPK3 protein]27222248
C017963vinyl carbamatediallyl sulfone inhibits the reaction [vinyl carbamate results in increased mutagenesis of KRAS gene]20205516
C017963vinyl carbamatevinyl carbamate results in increased mutagenesis of KRAS gene20205516
D014752Vinyl ChlorideCYP2E1 gene polymorphism promotes the reaction [Vinyl Chloride affects the mutagenesis of KRAS gene]12705718
D014752Vinyl ChlorideCYP2E1 gene polymorphism promotes the reaction [Vinyl Chloride results in increased mutagenesis of KRAS gene]17384900
D014752Vinyl ChlorideVinyl Chloride results in increased mutagenesis of KRAS gene10629081|1156360
D014752Vinyl ChlorideXRCC1 gene polymorphism promotes the reaction [Vinyl Chloride results in increased mutagenesis of KRAS gene]16881598
D014752Vinyl ChlorideKRAS gene polymorphism results in increased susceptibility to Vinyl Chloride12807761
C029297vinylidene chloridevinylidene chloride results in increased expression of KRAS mRNA26682919
D015215ZidovudineZidovudine results in increased mutagenesis of KRAS gene18800350
C017803zinc protoporphyrin[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of KRAS mRNA22839698
C088658zoledronic acidzoledronic acid results in increased expression of KRAS protein28871336

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003924GTPase activity-IEA-  
GO:0005515protein binding-IPI12732644  25416956  
GO:0005525GTP binding-IEA-  
GO:0019002GMP binding-IEA-  
GO:0019003GDP binding-IEA-  
GO:0030275LRR domain binding-IEA-  
GO:0044877protein-containing complex binding-IDA23209302  
GO ID GO Term Qualifier Evidence PubMed
GO:0000165MAPK cascade-TAS-  
GO:0001889liver development-IEA-  
GO:0001934positive regulation of protein phosphorylation-IMP22065586  
GO:0002223stimulatory C-type lectin receptor signaling pathway-TAS-  
GO:0007265Ras protein signal transduction-TAS-  
GO:0007565female pregnancy-IEA-  
GO:0008284positive regulation of cell proliferation-IMP23698361  
GO:0008542visual learning-IEA-  
GO:0010628positive regulation of gene expression-IMP22065586  
GO:0019221cytokine-mediated signaling pathway-IEA-  
GO:0021897forebrain astrocyte development-IEA-  
GO:0030036actin cytoskeleton organization-IEA-  
GO:0031647regulation of protein stability-IMP24623306  
GO:0032228regulation of synaptic transmission, GABAergic-IEA-  
GO:0035022positive regulation of Rac protein signal transduction-IEA-  
GO:0035900response to isolation stress-IEA-  
GO:0038002endocrine signaling-IEA-  
GO:0043406positive regulation of MAP kinase activity-IEA-  
GO:0043524negative regulation of neuron apoptotic process-IEA-  
GO:0045596negative regulation of cell differentiation-IEA-  
GO:0048169regulation of long-term neuronal synaptic plasticity-IEA-  
GO:0048873homeostasis of number of cells within a tissue-IEA-  
GO:0051000positive regulation of nitric-oxide synthase activity-IEA-  
GO:0051092positive regulation of NF-kappaB transcription factor activity-IEA-  
GO:0051146striated muscle cell differentiation-IEA-  
GO:0051384response to glucocorticoid-IEA-  
GO:0051385response to mineralocorticoid-IEA-  
GO:0060441epithelial tube branching involved in lung morphogenesis-IEA-  
GO:2000774positive regulation of cellular senescence-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005737cytoplasm-IDA23698361  
GO:0005739mitochondrion-IEA-  
GO:0005829cytosol-IEA-  
GO:0005886plasma membrane-TAS-  
GO:0005925focal adhesion-HDA21423176  
GO:0016020membrane-HDA19946888  
GO:0031234extrinsic component of cytoplasmic side of plasma membrane-IDA23698361  
GO:0045121membrane raft-IEA-  
KEGG ID KEGG Term
hsa04010MAPK signaling pathway
hsa04012ErbB signaling pathway
hsa04062Chemokine signaling pathway
hsa04320Dorso-ventral axis formation
hsa04360Axon guidance
hsa04370VEGF signaling pathway
hsa04530Tight junction
hsa04540Gap junction
hsa04650Natural killer cell mediated cytotoxicity
hsa04660T cell receptor signaling pathway
hsa04662B cell receptor signaling pathway
hsa04664Fc epsilon RI signaling pathway
hsa04720Long-term potentiation
hsa04722Neurotrophin signaling pathway
hsa04730Long-term depression
hsa04810Regulation of actin cytoskeleton
hsa04910Insulin signaling pathway
hsa04912GnRH signaling pathway
hsa04914Progesterone-mediated oocyte maturation
hsa04916Melanogenesis
hsa04960Aldosterone-regulated sodium reabsorption
hsa05160Hepatitis C
hsa05200Pathways in cancer
hsa05210Colorectal cancer
hsa05211Renal cell carcinoma
hsa05212Pancreatic cancer
hsa05213Endometrial cancer
hsa05214Glioma
hsa05215Prostate cancer
hsa05216Thyroid cancer
hsa05218Melanoma
hsa05219Bladder cancer
hsa05220Chronic myeloid leukemia
hsa05221Acute myeloid leukemia
hsa05223Non-small cell lung cancer
Reactome ID Reactome Term Evidence
R-HSA-109582HemostasisTAS
R-HSA-112399IRS-mediated signallingIEA
R-HSA-112412SOS-mediated signallingIEA
R-HSA-1168372Downstream signaling events of B Cell Receptor (BCR)TAS
R-HSA-1169092Activation of RAS in B cellsTAS
R-HSA-1226099Signaling by FGFR in diseaseTAS
R-HSA-1227986Signaling by ERBB2IEA
R-HSA-1227986Signaling by ERBB2TAS
R-HSA-1236382Constitutive Signaling by Ligand-Responsive EGFR Cancer VariantsTAS
R-HSA-1236394Signaling by ERBB4TAS
R-HSA-1250196SHC1 events in ERBB2 signalingIEA
R-HSA-1250347SHC1 events in ERBB4 signalingTAS
R-HSA-1266738Developmental BiologyTAS
R-HSA-1280218Adaptive Immune SystemTAS
R-HSA-1433557Signaling by SCF-KITTAS
R-HSA-162582Signal TransductionTAS
R-HSA-162582Signal TransductionIEA
R-HSA-1643685DiseaseTAS
R-HSA-1643713Signaling by EGFR in CancerTAS
R-HSA-166520Signaling by NTRKsIEA
R-HSA-166520Signaling by NTRKsTAS
R-HSA-167044Signalling to RASIEA
R-HSA-167044Signalling to RASTAS
R-HSA-168249Innate Immune SystemTAS
R-HSA-168256Immune SystemTAS
R-HSA-171007p38MAPK eventsTAS
R-HSA-171007p38MAPK eventsIEA
R-HSA-177929Signaling by EGFRTAS
R-HSA-179812GRB2 events in EGFR signalingTAS
R-HSA-180336SHC1 events in EGFR signalingTAS
R-HSA-186763Downstream signal transductionTAS
R-HSA-186797Signaling by PDGFTAS
R-HSA-187037Signaling by NTRK1 (TRKA)IEA
R-HSA-187037Signaling by NTRK1 (TRKA)TAS
R-HSA-187687Signalling to ERKsIEA
R-HSA-187687Signalling to ERKsTAS
R-HSA-190236Signaling by FGFRTAS
R-HSA-194138Signaling by VEGFTAS
R-HSA-1963640GRB2 events in ERBB2 signalingTAS
R-HSA-1963640GRB2 events in ERBB2 signalingIEA
R-HSA-202733Cell surface interactions at the vascular wallTAS
R-HSA-210993Tie2 SignalingTAS
R-HSA-212436Generic Transcription PathwayTAS
R-HSA-2172127DAP12 interactionsTAS
R-HSA-2179392EGFR Transactivation by GastrinTAS
R-HSA-2404192Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)IEA
R-HSA-2424491DAP12 signalingTAS
R-HSA-2428924IGF1R signaling cascadeIEA
R-HSA-2428928IRS-related events triggered by IGF1RIEA
R-HSA-2428933SHC-related events triggered by IGF1RIEA
R-HSA-2454202Fc epsilon receptor (FCERI) signalingTAS
R-HSA-2871796FCERI mediated MAPK activationTAS
R-HSA-372790Signaling by GPCRTAS
R-HSA-375165NCAM signaling for neurite out-growthTAS
R-HSA-388396GPCR downstream signallingTAS
R-HSA-416476G alpha (q) signalling eventsTAS
R-HSA-422475Axon guidanceTAS
R-HSA-4420097VEGFA-VEGFR2 PathwayTAS
R-HSA-5218921VEGFR2 mediated cell proliferationTAS
R-HSA-5621481C-type lectin receptors (CLRs)TAS
R-HSA-5621575CD209 (DC-SIGN) signalingTAS
R-HSA-5637810Constitutive Signaling by EGFRvIIITAS
R-HSA-5637812Signaling by EGFRvIII in CancerTAS
R-HSA-5637815Signaling by Ligand-Responsive EGFR Variants in CancerTAS
R-HSA-5654687Downstream signaling of activated FGFR1TAS
R-HSA-5654688SHC-mediated cascade:FGFR1TAS
R-HSA-5654693FRS-mediated FGFR1 signalingTAS
R-HSA-5654696Downstream signaling of activated FGFR2TAS
R-HSA-5654699SHC-mediated cascade:FGFR2TAS
R-HSA-5654700FRS-mediated FGFR2 signalingTAS
R-HSA-5654704SHC-mediated cascade:FGFR3TAS
R-HSA-5654706FRS-mediated FGFR3 signalingTAS
R-HSA-5654708Downstream signaling of activated FGFR3TAS
R-HSA-5654712FRS-mediated FGFR4 signalingTAS
R-HSA-5654716Downstream signaling of activated FGFR4TAS
R-HSA-5654719SHC-mediated cascade:FGFR4TAS
R-HSA-5654736Signaling by FGFR1TAS
R-HSA-5654738Signaling by FGFR2TAS
R-HSA-5654741Signaling by FGFR3TAS
R-HSA-5654743Signaling by FGFR4TAS
R-HSA-5655253Signaling by FGFR2 in diseaseTAS
R-HSA-5655291Signaling by FGFR4 in diseaseTAS
R-HSA-5655302Signaling by FGFR1 in diseaseTAS
R-HSA-5655332Signaling by FGFR3 in diseaseTAS
R-HSA-5658442Regulation of RAS by GAPsTAS
R-HSA-5663202Diseases of signal transductionTAS
R-HSA-5673000RAF activationTAS
R-HSA-5673001RAF/MAP kinase cascadeTAS
R-HSA-5674135MAP2K and MAPK activationTAS
R-HSA-5675221Negative regulation of MAPK pathwayTAS
R-HSA-5683057MAPK family signaling cascadesTAS
R-HSA-5684996MAPK1/MAPK3 signalingTAS
R-HSA-6802946Signaling by moderate kinase activity BRAF mutantsTAS
R-HSA-6802948Signaling by high-kinase activity BRAF mutantsTAS
R-HSA-6802949Signaling by RAS mutantsTAS
R-HSA-6802952Signaling by BRAF and RAF fusionsTAS
R-HSA-6802953RAS signaling downstream of NF1 loss-of-function variantsTAS
R-HSA-6802955Paradoxical activation of RAF signaling by kinase inactive BRAFTAS
R-HSA-6802957Oncogenic MAPK signalingTAS
R-HSA-6806834Signaling by METTAS
R-HSA-73857RNA Polymerase II TranscriptionTAS
R-HSA-74160Gene expression (Transcription)TAS
R-HSA-74751Insulin receptor signalling cascadeIEA
R-HSA-74752Signaling by Insulin receptorIEA
R-HSA-881907Gastrin-CREB signalling pathway via PKC and MAPKTAS
R-HSA-8848021Signaling by PTK6TAS
R-HSA-8849471PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinasesTAS
R-HSA-8851805MET activates RAS signalingTAS
R-HSA-8853334Signaling by FGFR3 fusions in cancerTAS
R-HSA-8853338Signaling by FGFR3 point mutants in cancerTAS
R-HSA-8878159Transcriptional regulation by RUNX3TAS
R-HSA-8951936RUNX3 regulates p14-ARFTAS
R-HSA-9006115Signaling by NTRK2 (TRKB)IEA
R-HSA-9006927Signaling by Non-Receptor Tyrosine KinasesTAS
R-HSA-9006934Signaling by Receptor Tyrosine KinasesTAS
R-HSA-9006934Signaling by Receptor Tyrosine KinasesIEA
R-HSA-9026519Activated NTRK2 signals through RASIEA
R-HSA-9028731Activated NTRK2 signals through FRS2 and FRS3IEA
R-HSA-983705Signaling by the B Cell Receptor (BCR)TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
25350766Epidemiology of goblet cell and microvesicular hyperplastic polyps. (2014 Dec)Qazi TMAm J Gastroenterol
28065467Lung Adenocarcinoma With MUC4 Expression Is Associated With Smoking Status, HER2 Protein Expression, and Poor Prognosis: Clinicopathologic Analysis of 338 Cases. (2017 Jul)Rokutan-Kurata MClin Lung Cancer
23242442Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers. (2013 Jan)Varghese AMJ Thorac Oncol
25158139Clinical and metabolic parameters in non-small cell lung carcinoma and colorectal cancer patients with and without KRAS mutations. (2014 Aug 25)Yilmaz AInt J Environ Res Public Health
26677401MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy. (2015)Garajova IClin Epigenetics
24442099Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status. (2014 Mar)Wang JJ Cancer Res Clin Oncol
21559688Genetic alterations in p53 and k-ras in lung-cancer in relation to histopathology of the tumor and smoking history of the patient. (1994 Nov)Ridanpaa MInt J Oncol
28103968[Gene Expression and Clinical Characteristics of Molecular Targeted Therapy in Non-small Cell Lung Cancer Patients in Shandong]. (2017 Jan 20)Qiao XZhongguo Fei Ai Za Zhi
25926253Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status. (2015 May-Jun)Sousa VRev Port Pneumol (2006)
22317764Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. (2012 Apr 1)Zhang YClin Cancer Res
29511884Podoplanin-positive cancer-associated fibroblast recruitment within cancer stroma is associated with a higher number of single nucleotide variants in cancer cells in lung adenocarcinoma. (2018 May)Nakasone SJ Cancer Res Clin Oncol
23027623MAP kinase genes and colon and rectal cancer. (2012 Dec)Slattery MLCarcinogenesis
28860576PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. (2017 Aug 31)Zhang MSci Rep
24466154Ion channel gene expression in lung adenocarcinoma: potential role in prognosis and diagnosis. (2014)Ko JHPLoS One
24920890Pulmonary adenocarcinoma mutation profile in smokers with smoking-related interstitial fibrosis. (2014)Primiani AInt J Chron Obstruct Pulmon Dis
24595526Mutation status of somatic EGFR and KRAS genes in Chinese patients with prostate cancer (PCa). (2014 May)Fu MVirchows Arch
25789627Identification of five driver gene mutations in patients with treatment-naive lung adenocarcinoma in Taiwan. (2015)Hsu KHPLoS One
26667343KRAS-Mutant Lung Cancers in the Era of Targeted Therapy. (2016)Naidoo JAdv Exp Med Biol
22548013Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center. (2012 Jan)Nguyen KSJ Oncol Pract
28468034[To evaluate the clinicopathologic characteristics and outcome of tumor cells spreading through air spaces in patients with adenocarcinoma of lung]. (2017 May 8)Sun PLZhonghua Bing Li Xue Za Zhi
24888607Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage. (2014 Sep)Kim TJJ Surg Oncol
25611230Erlotinib efficacy in NSCLC patients with high polysomy of chromosome 7 and EGFR/KRas wild-type tumors. (2015 Feb)Toffalorio FJ Thorac Oncol
22083596Stool DNA testing for the detection of pancreatic cancer: assessment of methylation marker candidates. (2012 May 15)Kisiel JBCancer
28468033[Clinicopathologic features and genetic profile of the redefined large cell lung carcinoma]. (2017 May 8)Hou LKZhonghua Bing Li Xue Za Zhi
26331813Differences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese population. (2015 Sep 1)Gou LYCancer
21839537Smoking history and lung carcinoma: KRAS mutation is an early hit in lung adenocarcinoma development. (2012 Feb)Thunnissen FBLung Cancer
20101149The Kras mutational spectra of chemically induced lung tumors in different inbred mice mimics the spectra of KRAS mutations in adenocarcinomas in smokers versus nonsmokers. (2010 Feb)Fritz JMJ Thorac Oncol
15572290Genotoxicity of tobacco smoke and tobacco smoke condensate: a review. (2004 Nov)DeMarini DMMutat Res
20659620Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course. (2010 Sep)Murakami SLung Cancer
26200269Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung. (2015 Aug)Shim HSJ Thorac Oncol
25773866Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. (2015 May)Tsai THLung Cancer
22537942Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues. (2012 Apr 26)Liang HJ Exp Clin Cancer Res
29167001[Association between the ALK Gene Status and the Efficacy of First-line Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma]. (2017 Nov 20)Chen MZhongguo Fei Ai Za Zhi
25349974PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. (2015 Jan 6)D'Incecco ABr J Cancer
23788756The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. (2013 Sep)Kim HRAnn Oncol
26483334[Detection and Analysis of EGFR and KRAS Mutations in the Patients with Lung Squamous Cell Carcinomas]. (2015 Oct 20)Zhang HZhongguo Fei Ai Za Zhi
27438512Driver Mutation Analysis and PD-L1 Expression in Synchronous Double Primary Lung Cancer. (2018 Apr)Jia XAppl Immunohistochem Mol Morphol
28921583Associations of alcohol intake, smoking, physical activity and obesity with survival following colorectal cancer diagnosis by stage, anatomic site and tumor molecular subtype. (2018 Jan 15)Jayasekara HInt J Cancer
25127677Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice. (2014 Nov)Hermann PCGastroenterology
26893860Genetic alterations in lung adenocarcinoma with a micropapillary component. (2016 Feb)Furukawa MMol Clin Oncol
21187500Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. (2010 Dec)Bonanno LAnticancer Res
26415993Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer. (2015 Nov)Mellema WWLung Cancer
24179496Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers. (2013 Nov)Takamochi KOncol Lett
22605530Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. (2012 Dec 1)Paik PKCancer
25567908Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. (2015 Aug 15)Drilon AClin Cancer Res
22199344Clinical significance of hypermethylation status in NSCLC: evaluation of a 30-gene panel in patients with advanced disease. (2011 Dec)Pesek MAnticancer Res
26423386Postdiagnostic intake of one-carbon nutrients and alcohol in relation to colorectal cancer survival. (2015 Nov)Lochhead PAm J Clin Nutr
28472989Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. (2017 May 4)Yang MJ Hematol Oncol
27440441Lung Adenocarcinoma: Predictive Value of KRAS Mutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided Ablation. (2017 Jan)Ziv ERadiology
26378065Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma. (2015 Nov)Huang JClin Chem
26601054Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice. (2015)Rangachari DCancer Treat Commun
25833149Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil. (2015)de Melo ACOncology
28881771Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative (18)F FDG-PET/CT metrics. (2017 Aug 8)Minamimoto ROncotarget
29631966MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy. (2018 Mar 17)Reis HClin Lung Cancer
22810899Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. (2013 Jan 15)Johnson MLCancer
27298405Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer. (2016 Aug 20)Rusthoven CGJ Clin Oncol
22222635Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma. (2012 May)Chung YTMod Pathol
21655907Lung cancers unrelated to smoking: characterized by single oncogene addiction? (2011 Aug)Suda KInt J Clin Oncol
26358312Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the "Hispanic paradox". (2015 Nov)Arrieta OLung Cancer
23802852Lung adenocarcinoma biomarker incidence in Hispanic versus non-Hispanic white patients. (2014 Mar)McQuitty EArch Pathol Lab Med
25243942Role of imaging biomarkers in predicting anaplastic lymphoma kinase-positive lung adenocarcinoma. (2015 Jan)Jeong CJClin Nucl Med
20061937Morphometric profiling of lung cancers-its association with clinicopathologic, biologic, and molecular genetic features. (2010 Feb)Okudela KAm J Surg Pathol
26202550Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma. (2015 Dec)Zheng DAnn Surg Oncol
27467545Adipophilin expression in lung adenocarcinoma is associated with apocrine-like features and poor clinical prognosis: an immunohistochemical study of 328 cases. (2017 Jan)Fujimoto MHistopathology
23573237Kras gene mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation: indicators of tumor staging and metastasis in adenocarcinomatous sporadic colorectal cancer in Indian population. (2013)Sinha RPLoS One
26860843Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer. (2016 Oct)Nicos MClin Transl Oncol
22978775Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients. (2012 Oct)Biaoxue RCurr Med Res Opin
23738762Pulmonary large cell carcinoma lacking squamous differentiation is clinicopathologically indistinguishable from solid-subtype adenocarcinoma. (2014 May)Hwang DHArch Pathol Lab Med
23877438CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma. (2013 Oct)Matsuura SOncol Rep
24850843FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. (2014 Aug 1)Wang RClin Cancer Res
29270615Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. (2018 Feb 1)Lee CKJAMA Oncol
29301504Nine primary malignant neoplasms-involving the esophagus, stomach, colon, rectum, prostate, and external ear canal-without microsatellite instability: a case report. (2018 Jan 4)Arakawa KBMC Cancer
18391747Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. (2008 Jun)Motoi NAm J Surg Pathol
24760004Frequent mutations in EGFR, KRAS and TP53 genes in human lung cancer tumors detected by ion torrent DNA sequencing. (2014)Cai XPLoS One
26536196Clinical Implications of Variant ALK FISH Rearrangement Patterns. (2015 Nov)Gao XJ Thorac Oncol
27575421Clinicopathological, Immunohistochemical, and Genetic Features of Primary Lung Adenocarcinoma Occurring in the Setting of Usual Interstitial Pneumonia Pattern. (2016 Dec)Masai KJ Thorac Oncol
23988622Comparison of EGFR signaling pathway somatic DNA mutations derived from peripheral blood and corresponding tumor tissue of patients with advanced non-small-cell lung cancer using liquidchip technology. (2013 Nov)Zhang HJ Mol Diagn
27008036Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung Cancer. (2016)Saber APLoS One
23988776EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. (2014 Mar)Warth AEur Respir J
25366782Associations between clinical characteristics and oncogene expression in patients with non-small cell lung cancer. (2014 Oct 31)Han YGenet Mol Res
22707299Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. (2012 Nov)Ren SCell Biochem Biophys
26582224[Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma]. (2015 Nov)Zhang HZhongguo Fei Ai Za Zhi
26359571FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients. (2015 Dec)Lee SMClin Nucl Med
24055406Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning. (2013 Nov)Hosgood HD 3rdRespir Med
20688547Backtracking RAS mutations in high hyperdiploid childhood acute lymphoblastic leukemia. (2010 Oct 15)Wiemels JLBlood Cells Mol Dis
25351745MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. (2015 Apr 15)Arcila MEClin Cancer Res
29723602Non-small cell lung cancers with Isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations. (2018 Apr 30)Toth LNHum Pathol
25657019BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers. (2015 May)Couraud SEur Respir J
22430133Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer. (2011-2012)Xu JCancer Biomark
21062932Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. (2010 Nov 15)Camidge DRClin Cancer Res
26955281The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations. (2016)Zheng DOnco Targets Ther
21592614EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung. (2011 Dec)Jia XLLung Cancer
18296105Cigarette smoking and KRAS oncogene mutations in sporadic colorectal cancer: results from the Netherlands Cohort Study. (2008 Mar 29)Weijenberg MPMutat Res
20507599Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. (2010 May 27)Baba YMol Cancer
22975805The transcriptional landscape and mutational profile of lung adenocarcinoma. (2012 Nov)Seo JSGenome Res
21387273Clinicopathological features of lung adenocarcinoma with KRAS mutations. (2011 Sep 15)Kakegawa SCancer
25870798Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. (2015 Apr)Kohno TTransl Lung Cancer Res
26164066Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma. (2015 Sep)Preusser MEur J Cancer
21617709From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy. (2011 Mar-Apr)Mazzoni FTumori
26601720Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis. (2016 Feb)Bjaanaes MMMol Oncol
28256572Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities. (2017 Jun)Yoshida AMod Pathol
14581353Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. (2003 Oct 15)Miller CTClin Cancer Res
28685219Clinicopathological Significance of Micropapillary Pattern in Lung Adenocarcinoma. (2018 Jul)Pyo JSPathol Oncol Res
28676214DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel. (2017 Aug)Takamochi KLung Cancer
28454347Effect of cigarette smoke exposure and mutant Kras overexpression on pancreatic cell proliferation. (2017 Mar)Glauert HPOncol Lett
16533793Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. (2006 Mar 1)Tam IYClin Cancer Res
25152623Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma. (2014)Hu HOnco Targets Ther
28625654LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer. (2017 Jun)Imperatori ALung Cancer
25634006Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). (2015 May)Arrieta OJ Thorac Oncol
27859136KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer. (2017 Feb 15)Nagy AInt J Cancer
19351817Genetic mutations associated with cigarette smoking in pancreatic cancer. (2009 Apr 15)Blackford ACancer Res
25557162Cytomorphological features of ALK-positive lung adenocarcinomas: psammoma bodies and signet ring cells. (2015 Mar)Pareja FCancer Cytopathol
25288236Molecular alterations in non-small cell lung carcinomas of the young. (2014 Dec)VandenBussche CJHum Pathol
29526824Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors. (2018 Jun)Parra ERJ Thorac Oncol
25439691Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. (2014 Nov)Ramalingam SSLancet Oncol
29533466The advanced glycation end-product N() -carboxymethyllysine promotes progression of pancreatic cancer: implications for diabetes-associated risk and its prevention. (2018 Jun)Menini SJ Pathol
29247171Computer-Aided Nodule Assessment and Risk Yield (CANARY) may facilitate non-invasive prediction of EGFR mutation status in lung adenocarcinomas. (2017 Dec 15)Clay RSci Rep
16863509EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. (2006 Aug)Yokoyama TCancer Sci
21615826Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma. (2011 Jul)Liu QWDis Esophagus
19596959Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status. (2009 Jul)Pesek MAnticancer Res
19841986Molecular characterization of chronic obstructive pulmonary disease-related non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling. (2010 Mar)Suzuki MAnn Surg Oncol
26473645Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. (2015 Dec)Calles AJ Thorac Oncol
24932237SLC23A2-05 (rs4987219) and KRAS-LCS6 (rs61764370) polymorphisms in patients with squamous cell carcinoma of the head and neck. (2014 Jun)Santiago MBOncol Lett
26350052Molecular Testing in Multiple Synchronous Lung Adenocarcinomas: Case Report and Literature Review. (2016 Feb)Rafael OCInt J Surg Pathol
27987580Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers. (2016 Dec)Chapman AMLung Cancer
18549475Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma. (2008 Jun 12)Blons HBMC Med Genomics
24077454CDKN2A/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non-small-cell lung cancer. (2013 Nov)Tam KWJ Thorac Oncol
24729716Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. (2014)Li HOnco Targets Ther
23515407Characteristics of lung cancers harboring NRAS mutations. (2013 May 1)Ohashi KClin Cancer Res
17575133Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. (2007 Jun 15)Mounawar MCancer Res
29083024Pulmonary Langerhans' cell histiocytosis in adults. (2017)Radzikowska EAdv Respir Med
25278450Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome. (2014 Dec 1)Karlsson AClin Cancer Res
25280443Association between molecular subtypes of colorectal cancer and patient survival. (2015 Jan)Phipps AIGastroenterology
27008586Clinicopathologic Characteristics of Patients with HER2 Insertions in Non-small Cell Lung Cancer. (2017 Jan)Bu SAnn Surg Oncol
23204236CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. (2013 Jan 15)Saintigny PCancer Res
24994038Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer. (2014 Dec)Deng LLJ Cancer Res Clin Oncol
27182622KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients. (2017 Feb)Gao WMol Carcinog
27020204Associations between the IASLC/ATS/ERS lung adenocarcinoma classification and EGFR and KRAS mutations. (2016 Jan)Clay TDPathology
21336183Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. (2011 Apr)Camidge DRJ Thorac Oncol
23919423Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients. (2013 Oct)Xia NExp Lung Res
28776576GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas. (2017 Dec)Ritterhouse LLMod Pathol
23806795Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist? (2013 Sep)Bauml JLung Cancer
24205279Genomic and transcriptional alterations in lung adenocarcinoma in relation to EGFR and KRAS mutation status. (2013)Planck MPLoS One
25582278EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity. (2015 Mar)Yang YLung Cancer
29127119RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition. (2018 Mar 15)Hayashi TClin Cancer Res
25361983Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth. (2015 Jan)Kobayashi YAnn Oncol
23098378Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. (2013 Jan)Li HLung Cancer
25222473Increased NQO1 but not c-MET and survivin expression in non-small cell lung carcinoma with KRAS mutations. (2014 Sep 12)Yilmaz AInt J Environ Res Public Health
26200454Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. (2015 Oct)Gautschi OJ Thorac Oncol
27467949PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. (2016 May)Scheel AHOncoimmunology
19855375Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. (2010 Feb)Dacic SMod Pathol
22613842Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. (2012 Jul)Selamat SAGenome Res
18932251Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications. (2008 Dec 1)Wu CCCancer
27262212Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis. (2016 Aug)Noonan SAJ Thorac Oncol
23629442High-grade lung adenocarcinoma with fetal lung-like morphology: clinicopathologic, immunohistochemical, and molecular analyses of 17 cases. (2013 Jun)Morita SAm J Surg Pathol
27992614A Single Nucleotide Polymorphism in the RASGRF2 Gene Is Associated with Alcoholic Liver Cirrhosis in Men. (2016)Novo-Veleiro IPLoS One
27449344Survival of Patients with Advanced Non-Small Cell Lung Cancer Enrolled in Clinical Trials. (2016)Arrieta OOncology
22659961Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure. (2012 Aug)Arrieta OJ Thorac Oncol
25415430Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. (2015 Mar)Yu HAJ Thorac Oncol
22399565Loss of transforming growth factor beta type II receptor increases aggressive tumor behavior and reduces survival in lung adenocarcinoma and squamous cell carcinoma. (2012 Apr 15)Malkoski SPClin Cancer Res
23376323Clinical subtypes and molecular characteristics of serrated polyposis syndrome. (2013 Jun)Guarinos CClin Gastroenterol Hepatol
25862146PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy. (2015 Jun)Chang YLLung Cancer
25588859Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report. (2015 May 26)Campos-Gomez SInt J Biol Markers
19096302Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. (2009 Jan)Kosaka TJ Thorac Oncol
27699239Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. (2016 Sep 8)Lizotte PHJCI Insight
17904685Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. (2008 Jan)Kim YTLung Cancer
28513466Non-small cell lung cancer - mutations, targeted and combination therapy. (2017 May 17)Kutkowska JPostepy Hig Med Dosw (Online)
2547647The molecular genetics of human lung cancer. (1989 May)Slebos RJEur Respir J
28423587The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC. (2017 Apr 4)Yang HOncotarget
18794081Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. (2008 Sep 15)Riely GJClin Cancer Res
24768329Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy. (2014 Jul)Cserepes MEur J Cancer
24474939Risk factors for pancreatic cancer: underlying mechanisms and potential targets. (2013)Kolodecik TFront Physiol
24390215Cribriform adenocarcinoma of the lung: clinicopathologic, immunohistochemical, and molecular analysis of 15 cases of a distinctive morphologic subtype of lung adenocarcinoma. (2014 Aug)Mackinnon AC JrMod Pathol
23709419The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinoma. (2013 Jul)Kim HRYonsei Med J
21422434Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504). (2011 May 1)Ramalingam SSJ Clin Oncol
29413057Tumor biomarker testing in non-small-cell lung cancer: A decade of change. (2018 Feb)VanderLaan PALung Cancer
17060486EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. (2007 Jan)van Zandwijk NAnn Oncol
22425916EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. (2012 Apr)Milella MJ Thorac Oncol
27100677Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression. (2016)Sato KPLoS One
24193009EGFR autophosphorylation but not protein score correlates with histologic and molecular subtypes in lung adenocarcinoma. (2013 Dec)Moldvay JDiagn Mol Pathol
26767032Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma. (2014 Sep)Zhu JThorac Cancer
26739511Elderly male smokers with right lung tumors are viable candidates for KRAS mutation screening. (2016 Jan 7)Yang YSci Rep
21558399Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. (2011 May 15)Rizvi NAClin Cancer Res
23887294KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas. (2014 Feb)Krasinskas AMMod Pathol
15674422RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia. (2005 Mar)Wiemels JLLeukemia
18166835EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. (2008 Jan)Inamura KJ Thorac Oncol
27437773Consensus of gene expression phenotypes and prognostic risk predictors in primary lung adenocarcinoma. (2016 Aug 16)Ringner MOncotarget
25267753How long is long enough? Extended anticoagulation for the treatment of cancer-associated deep vein thrombosis. (2014 Nov 10)Zwicker JIJ Clin Oncol
24571676RAS mutations in early age leukaemia modulated by NQO1 rs1800566 (C609T) are associated with second-hand smoking exposures. (2014 Feb 26)Andrade FGBMC Cancer
17384680Prevalence and specificity of LKB1 genetic alterations in lung cancers. (2007 Aug 30)Matsumoto SOncogene
24828667Small-cell lung cancers in patients who never smoked cigarettes. (2014 Jun)Varghese AMJ Thorac Oncol
15604253Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. (2004 Dec 15)Kosaka TCancer Res
25129367Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE). (2014 Oct)Sarosi VLung Cancer
28911955Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patients. (2017 Dec)Gimbrone NTJ Thorac Oncol
22666783Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients. (2012)Bacchi CEClinics (Sao Paulo)
23835703Maintenance therapy for advanced lung cancer: who, what, and when? (2013 Aug 20)Gerber DEJ Clin Oncol
26530529Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations. (2015 Nov 24)Li WOncotarget
25695224Somatic STK11 and concomitant STK11/KRAS mutational frequency in stage IV lung adenocarcinoma adrenal metastases. (2015 Mar)Gleeson FCJ Thorac Oncol
26102513Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma. (2015)Shan LPLoS One
29246019Clinicopathological and genetic characteristics of pulmonary large cell carcinoma under 2015 WHO classification: a pilot study. (2017 Nov 21)Liu ROncotarget
28043144Association of EGFR and KRAS mutations with expression of p-AKT, DR5 and DcR1 in non-small cell lung cancer. (2017)Zhao XDNeoplasma
12917199Screening of homologous recombination gene polymorphisms in lung cancer patients reveals an association of the NBS1-185Gln variant and p53 gene mutations. (2003 Aug)Medina PPCancer Epidemiol Biomarkers Prev
27033384[Mutation status of epidermal growth factor receptor and KRAS gene in non-small cell lung cancers at Xuanwei regions of Yunnan Province]. (2016 Apr 8)Yang CSZhonghua Bing Li Xue Za Zhi
24446743Human papilloma virus detection and typing in 334 lung cancer patients. (2014 Jul)Sagerup CMActa Oncol
29413048Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells? (2018 Feb)Zhou FLung Cancer
27293837Surgical treatment of synchronous multiple primary lung cancers: a retrospective analysis of 122 patients. (2016 Jun)Liu MJ Thorac Dis
27227356Former smokers with non-small-cell lung cancers: a comprehensive investigation of clinicopathologic characteristics, oncogenic drivers, and prognosis. (2016 Aug)Zheng SCancer Med
27033383[Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer]. (2016 Apr 8)Chen LFZhonghua Bing Li Xue Za Zhi
17452061Up-regulation of PTEN at the transcriptional level is an adverse prognostic factor in female lung adenocarcinomas. (2007 Aug)Inamura KLung Cancer
23932486Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. (2013 Oct)Yamaguchi NLung Cancer
27161973Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study. (2016 Jul 1)Kawaguchi TJ Clin Oncol
26632382Concomitance of P-gp/LRP Expression with EGFR Mutations in Exons 19 and 21 in Non-Small Cell Lung Cancers. (2016 Jan)Wei HYonsei Med J
26711930Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations. (2016 Jan)Tissot CLung Cancer
26622749Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma. (2015 Sep)Soh JOncol Lett
27565922Hot spot mutations in Finnish non-small cell lung cancers. (2016 Sep)Maki-Nevala SLung Cancer
22768234Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. (2012)An SJPLoS One
23547084Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III Trial N0147. (2013 Jun 1)Phipps AIJ Clin Oncol
25007143Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts. (2014 Dec)Boland JMAm J Surg Pathol
21521776Genomic profiles specific to patient ethnicity in lung adenocarcinoma. (2011 Jun 1)Broet PClin Cancer Res
23150706RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. (2012 Dec 10)Wang RJ Clin Oncol
23341890Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. (2013)Li YPLoS One
27086595Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases. (2016 May)Lee TJ Pathol Transl Med
23435014Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma. (2013 May)Andujar PMutagenesis
23154553Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. (2012 Dec)D'Angelo SPJ Thorac Oncol
21150464Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer. (2011 Jan)Sasaki HJ Thorac Oncol
24279718Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report. (2013 Nov 26)Rossing HHBMC Res Notes
26915300Mutually exclusive extracellular signal-regulated kinase pathway mutations are present in different stages of multi-focal pulmonary Langerhans cell histiocytosis supporting clonal nature of the disease. (2016 Sep)Kamionek MHistopathology
24748981APOBEC3B gene overexpression in non-small-cell lung cancer. (2014 May)Sasaki HBiomed Rep
26622815Determination of EGFR and KRAS mutational status in Greek non-small-cell lung cancer patients. (2015 Oct)Papadopoulou EOncol Lett
27258560The Role of SATB2 as a Diagnostic Marker of Sinonasal Intestinal-type Adenocarcinoma. (2018 Feb)Skalova AAppl Immunohistochem Mol Morphol
25013126Excess of proximal microsatellite-stable colorectal cancer in African Americans from a multiethnic study. (2014 Sep 15)Xicola RMClin Cancer Res
17409862Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. (2006 Mar)Tsao ASJ Thorac Oncol
22267755Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort. (2012 Jul)Scoccianti CEur Respir J
24743704Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts. (2014 May 27)Li SBr J Cancer
26208325Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations. (2015)Chatziandreou IPLoS One
25745045No impact of passive smoke on the somatic profile of lung cancers in never-smokers. (2015 May)Couraud SEur Respir J
28280984Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. (2018 Jan)Saito MSurg Today
25911935[Genetic aspects of pancreatic cancer]. (2014)Grigor'eva INEksp Klin Gastroenterol
18824180Fetal-juvenile origins of point mutations in the adult human tracheal-bronchial epithelium: absence of detectable effects of age, gender or smoking status. (2008 Nov 10)Sudo HMutat Res
26273395Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements. (2015 Jul)Wu SThorac Cancer
25127693A let-7 microRNA polymorphism in the KRAS 3'-UTR is prognostic in oropharyngeal cancer. (2014 Oct)De Ruyck KCancer Epidemiol
26775573[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)]. (2016 Jan)Hamard CAnn Pathol
21483012Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. (2011 May 20)Paik PKJ Clin Oncol
29650325Improving the genetic signature of prostate cancer, the somatic mutations. (2018 Jun)Martinez-Gonzalez LJUrol Oncol
22887466Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. (2013 Jan)Shaw ATAnn Oncol
29530732Clinical and Molecular Predictors of PD-L1 Expression in Non-Small-Cell Lung Cancer: Systematic Review and Meta-analysis. (2018 Feb 21)Petrelli FClin Lung Cancer
23302304[Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system]. (2012 Oct)Gao JZhonghua Bing Li Xue Za Zhi
27655296Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia. (2016 Sep 21)Brcic LDiagn Pathol
19270482EGFR and KRAS mutations in patients with adenocarcinoma of the lung. (2009 Mar)Jang TWKorean J Intern Med
22464348Lung cancer in never smokers--a review. (2012 Jun)Couraud SEur J Cancer
19787214The status of KRAS mutations in patients with non-small cell lung cancers from mainland China. (2009 Nov)Li MOncol Rep
23014527Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. (2012 Nov 15)Dogan SClin Cancer Res
18594528Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. (2008 Jul 22)Koivunen JPBr J Cancer
23619604KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. (2013 Oct)Rekhtman NMod Pathol
22349355Cigarette smoking and colorectal cancer risk by KRAS mutation status among older women. (2012 May)Samadder NJAm J Gastroenterol
25664625Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. (2015 May)Lohinai ZJ Thorac Oncol
25706305Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis. (2015)Zhao FPLoS One
25738220Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. (2015 May)Sholl LMJ Thorac Oncol
25118293Alterations of insulin-like growth factor-1 receptor gene copy number and protein expression are common in non-small cell lung cancer. (2014 Nov)Tran TNJ Clin Pathol
22507644Human papillomavirus and gene mutations in head and neck squamous carcinomas. (2012 May)Friedland PANZ J Surg
29713040Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma. (2018 Apr 30)Chan AWHMod Pathol
28898697Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by KRAS Mutations. (2017 Sep 11)Vaz MCancer Cell
19234440EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. (2009 Apr)Inamura KMod Pathol
26762747Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients. (2016 Jan)Michels SJ Thorac Oncol
23723294Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). (2013 Sep)Dearden SAnn Oncol
28476195Tobacco Smoke and Ras Mutations Among Latino and Non-Latino Children with Acute Lymphoblastic Leukemia. (2016 Nov)Kaur MArch Med Res
25234657Tongue carcinoma infrequently harbor common actionable genetic alterations. (2014 Sep 19)Tan DSBMC Cancer
28840008Differences between low and high grade fetal adenocarcinoma of the lung: a clinicopathological and molecular study. (2017 Jul)Zhang JJ Thorac Dis
28881815Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations. (2017 Aug 8)Dugay FOncotarget
25734337Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. (2015 Mar 3)Grabner BNat Commun
29290777Classifying Non-Small Cell Lung Cancer by Status of Programmed Cell Death Ligand 1 and Tumor-Infiltrating Lymphocytes on Tumor Cells. (2018)Cui SJ Cancer
27568346Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment. (2016 Nov)Huynh TGJ Thorac Oncol
18418018EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients. (2008 Apr)Wang ZOnkologie
25456736Recurrent TERT promoter mutations in non-small cell lung cancers. (2014 Dec)Ma XLung Cancer
21772844Molecular mechanisms of cigarette smoke-induced proliferation of lung cells and prevention by vitamin C. (2011)Dey NJ Oncol
27794398Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation. (2016 Nov)Tanizaki JLung Cancer
28345958Macrophage Elastase Induces TRAIL-mediated Tumor Cell Death through Its Carboxy-Terminal Domain. (2017 Aug 1)Dandachi NAm J Respir Crit Care Med
21847063A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. (2011 Aug)Riely GJJ Thorac Oncol
24331409KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies. (2014 Feb)Maus MKLung Cancer
26745602HDAC3 mediates smoking-induced pancreatic cancer. (2016 Feb 16)Edderkaoui MOncotarget
19667264Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. (2009 Sep 10)Shaw ATJ Clin Oncol
25970685Pulmonary adenocarcinoma in situ: analyses of a large series with reference to smoking, driver mutations, and receptor tyrosine kinase pathway activation. (2015 Jul)Sato SAm J Surg Pathol
19559099Mustard gas exposure and carcinogenesis of lung. (2009 Aug)Hosseini-khalili AMutat Res
18090579Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. (2007 Dec)Boldrini LJ Thorac Oncol
26851496Incidence of Lung Adenocarcinoma Biomarker in a Caribbean and African Caribbean Population. (2016 May)Leduc NJ Thorac Oncol
24863005KRAS oncogene substitutions in Korean NSCLC patients: clinical implication and relationship with pAKT and RalGTPases expression. (2014 Aug)Kim EYLung Cancer
24097870EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. (2013 Dec 1)Behrens CClin Cancer Res
22736493Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations. (2012 Oct)Shaozhang ZGenes Chromosomes Cancer
29137260Pathologic subtype-defined prognosis is dependent on both tumor stage and status of oncogenic driver mutations in lung adenocarcinoma. (2017 Oct 10)Dong YOncotarget
28914263Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma. (2018 Feb)Tang ZMod Pathol
28338535Lung Cancers Associated With Cystic Airspaces: Natural History, Pathologic Correlation, and Mutational Analysis. (2017 May)Fintelmann FJJ Thorac Imaging
29191596PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. (2017 Oct)Brody RLung Cancer
21030453Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer. (2011 Jan)Cadranel JEur Respir J
22882865Downregulating activated epidermal growth factor receptor has no effect on RBM5 expression. (2012 Jul)Masilamani TJChin Med J (Engl)
26064214Correlation between smoking history and molecular pathways in sporadic colorectal cancer: a meta-analysis. (2015)Chen KInt J Clin Exp Med
25488863Alterations of a spectrum of driver genes in female Chinese patients with advanced or metastatic squamous cell carcinoma of the lung. (2015 Feb)Qiong ZLung Cancer
24643899Clinicopathology and genetic profile of synchronous multiple small adenocarcinomas: implication for surgical treatment of an uncommon lung malignancy. (2014 Aug)Lin MWAnn Surg Oncol
24163741Molecular biology of lung cancer. (2013 Oct)Cooper WAJ Thorac Dis
21865138APC and KRAS mutations in distal colorectal polyps are related to smoking habits in men: results of a cross-sectional study. (2011 Sep)Martinez FClin Transl Oncol
22200795Overexpression of GLUT1 correlates with Kras mutations in lung carcinomas. (2012 Mar)Sasaki HMol Med Rep
24300132Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. (2014 Feb)Sun JMLung Cancer
23887156ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. (2013 Sep)Sholl LMAm J Surg Pathol
22969966Braf and erbB2 mutations correlate with smoking status in lung cancer patients. (2012 May)Sasaki HExp Ther Med